The CHANCE study was a multicenter, randomized, double-blind, parallel-controlled trial. The primary outcome was a new stroke (including ischemic and hemorrhagic events) in the clopidogrel/aspirin group versus aspirin alone within three months. The results of the CHANCE study were published in the New England Journal of Medicine, the world's top medical journal. It was the first Chinese neurology article published in the New England Journal of Medicine and was the first study to rewrite American guidelines about the neurological diseases.
At the 2018 International Stroke Conference which was held in Los Angeles, USA, the CHANCE research led by Professor Wang Yongjun of Beijing Tiantan Hospital was cited as the high-level evidence for the latest release of the American Acute Ischemic Stroke Treatment Guidelines (2018). This is the second time for the CHANCE trial to be cited by the American guidelines, and it was also cited in the 2014 American guidelines for secondary prevention of stroke and transient ischemic attacks. The CHANCE study was cited in the most authoritative American guideline about the international cerebrovascular disease, which means that the guidelines of other countries and regions may be also updated. The treatment from China may be popularized in clinical treatment worldwide, benefiting patients with acute mild ischemic cerebrovascular disease worldwide.